358 related articles for article (PubMed ID: 16234341)
1. A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system.
Guthrie H; Livingston FS; Gubler U; Garippa R
J Biomol Screen; 2005 Dec; 10(8):832-40. PubMed ID: 16234341
[TBL] [Abstract][Full Text] [Related]
2. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
3. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
Hancox JC; McPate MJ; El Harchi A; Zhang YH
Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.
Kang J; Chen XL; Wang H; Ji J; Cheng H; Incardona J; Reynolds W; Viviani F; Tabart M; Rampe D
Mol Pharmacol; 2005 Mar; 67(3):827-36. PubMed ID: 15548764
[TBL] [Abstract][Full Text] [Related]
5. Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade.
Deacon M; Singleton D; Szalkai N; Pasieczny R; Peacock C; Price D; Boyd J; Boyd H; Steidl-Nichols JV; Williams C
J Pharmacol Toxicol Methods; 2007; 55(3):238-47. PubMed ID: 17141530
[TBL] [Abstract][Full Text] [Related]
6. Automated Patch-Clamp Methods for the hERG Cardiac Potassium Channel.
Houtmann S; Schombert B; Sanson C; Partiseti M; Bohme GA
Methods Mol Biol; 2017; 1641():187-199. PubMed ID: 28748465
[TBL] [Abstract][Full Text] [Related]
7. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.
Hanson LA; Bass AS; Gintant G; Mittelstadt S; Rampe D; Thomas K
J Pharmacol Toxicol Methods; 2006; 54(2):116-29. PubMed ID: 16843688
[TBL] [Abstract][Full Text] [Related]
8. A history of the role of the hERG channel in cardiac risk assessment.
Rampe D; Brown AM
J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
[TBL] [Abstract][Full Text] [Related]
9. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
Polak S; Wiśniowska B; Brandys J
J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
[TBL] [Abstract][Full Text] [Related]
10. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects.
Zünkler BJ
Pharmacol Ther; 2006 Oct; 112(1):12-37. PubMed ID: 16647758
[TBL] [Abstract][Full Text] [Related]
11. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
Finlayson K; Witchel HJ; McCulloch J; Sharkey J
Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
[TBL] [Abstract][Full Text] [Related]
12. A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel.
Schmalhofer WA; Swensen AM; Thomas BS; Felix JP; Haedo RJ; Solly K; Kiss L; Kaczorowski GJ; Garcia ML
Assay Drug Dev Technol; 2010 Dec; 8(6):714-26. PubMed ID: 21158686
[TBL] [Abstract][Full Text] [Related]
13. QT interval prolongation and cardiac risk assessment for novel drugs.
Picard S; Lacroix P
Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
[TBL] [Abstract][Full Text] [Related]
14. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the HERG channel by droperidol depends on channel gating and involves the S6 residue F656.
Luo T; Luo A; Liu M; Liu X
Anesth Analg; 2008 Apr; 106(4):1161-70, table of contents. PubMed ID: 18349188
[TBL] [Abstract][Full Text] [Related]
16. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
Towart R; Linders JT; Hermans AN; Rohrbacher J; van der Linde HJ; Ercken M; Cik M; Roevens P; Teisman A; Gallacher DJ
J Pharmacol Toxicol Methods; 2009; 60(1):1-10. PubMed ID: 19439185
[TBL] [Abstract][Full Text] [Related]
17. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.
Hoffmann P; Warner B
J Pharmacol Toxicol Methods; 2006; 53(2):87-105. PubMed ID: 16289936
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
19. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
20. hERG channel trafficking: novel targets in drug-induced long QT syndrome.
Dennis A; Wang L; Wan X; Ficker E
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1060-3. PubMed ID: 17956279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]